Pedunculopontine Nucleus (PPN)
Introduction
Pedunculopontine Nucleus (Ppn) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The pedunculopontine nucleus (PPN), also known as the pedunculopontine tegmental nucleus (PPTg or PPTn), is a collection of cholinergic, glutamatergic, and GABAergic neurons located in the upper brainstem at the junction of the midbrain and pons. The PPN is a key component of the mesencephalic locomotor region (MLR), a brainstem center that controls locomotion, postural control, and gait initiation ([Takakusaki et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26972579/)). It is also critically involved in sleep-wake regulation, arousal, and the modulation of basal ganglia output. In neurodegenerative diseases — particularly Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy — the PPN undergoes significant cholinergic neuron loss, contributing to the debilitating axial motor symptoms (gait freezing, postural instability, falls) and sleep disturbances that are often refractory to dopaminergic therapy ([Pahapill & Bhagwan, 2000](https://pubmed.ncbi.nlm.nih.gov/10704927/); [Pienaar et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31749893/)). [@pahapill2000]
Anatomy and Organization
Location and Gross Structure
The PPN is situated in the dorsolateral mesopontine tegmentum, extending from the caudal border of the substantia nigra pars reticulata to the rostral pons. It lies adjacent to the decussation of the superior cerebellar peduncle and lateral to the medial lemniscus. The PPN spans approximately 6–8 mm in the rostrocaudal axis in the human brain ([Olszewski & Baxter, 1982](https://pubmed.ncbi.nlm.nih.gov/7057920/)). [@pienaar2019]
Subdivisions
The PPN is divided into two major compartments based on cell density and composition: [@mesulam1983]
- Pars compacta (PPNc): The caudal, denser portion containing the highest concentration of large cholinergic neurons. This is the primary cholinergic cell group of the PPN and is designated Ch5 in the Mesulam cholinergic nomenclature ([Mesulam et al., 1983](https://pubmed.ncbi.nlm.nih.gov/6619325/)).
- Pars dissipata (PPNd): The rostral, more diffuse portion with scattered cholinergic neurons intermixed with glutamatergic and GABAergic populations. This zone blends with the cuneiform nucleus dorsally and the substantia nigra rostrally.
Neuronal Composition
The PPN contains three major neuronal populations, each with distinct functional roles ([Martinez-Gonzalez et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21383508/)): [@martinezgonzalez2011]
- Cholinergic neurons (~25–30% of total): Large, multipolar neurons expressing choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT). These are the defining cell type of the PPN and number approximately 10,000–15,000 per side in the healthy human brain.
- Glutamatergic neurons (~35–40%): Express vesicular glutamate transporter 2 (VGLUT2). Involved in cortical activation and locomotor drive.
- GABAergic neurons (~30–35%): Express glutamic acid decarboxylase (GAD). Function as local inhibitory interneurons and provide inhibitory output.
Connectivity
The PPN receives convergent input from multiple motor and limbic structures ([Mena-Segovia et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15325346/)): [@menasegovia2004]
- basal ganglia: Massive GABAergic input from the substantia nigra pars reticulata (SNr) and globus pallidus interna (GPi). These are the primary basal ganglia outputs that tonically inhibit the PPN, and their excessive activity in parkinsonian states is believed to suppress PPN function.
- Subthalamic nucleus: Glutamatergic excitatory input that modulates PPN activity.
- Motor cortex: Direct cortico-tegmental projections that may initiate locomotion.
- Spinal cord: Ascending proprioceptive and nociceptive information.
- Hypothalamus and limbic structures: Integrating motivational state with motor output.
Efferent Projections
The PPN has remarkably widespread ascending and descending projections: [@garciarill1991]
- Ascending cholinergic projections: To the thalamus (intralaminar, reticular, and relay nuclei), substantia nigra pars compacta, subthalamic nucleus, striatum, and basal forebrain. These projections modulate thalamocortical arousal, basal ganglia processing, and cortical activation.
- Descending projections: To the pontine and medullary reticular formation, which in turn project to the spinal cord locomotor pattern generators. This pathway is the primary mechanism by which the PPN initiates and modulates locomotion.
- Cerebellar projections: Indirect connections via the pontine nuclei link PPN activity to cerebellar motor coordination.
Normal Functions
Locomotion and Gait Control
The PPN is a central component of the mesencephalic locomotor region (MLR), which, when electrically stimulated, produces coordinated locomotion in experimental animals ([Garcia-Rill, 1991](https://pubmed.ncbi.nlm.nih.gov/1786666/)). The MLR does not generate locomotor patterns directly; rather, it activates spinal locomotor pattern generators through the medullary reticular formation. The PPN integrates signals from the basal ganglia, cortex, and cerebellum to regulate: [@steriade1990]
- Gait initiation and termination
- Locomotor speed and cadence
- Postural tone and balance
- Stepping pattern (walking, running, jumping)
Sleep-Wake Regulation
PPN cholinergic neurons play a critical role in generating REM sleep and maintaining wakefulness ([Steriade et al., 1990](https://pubmed.ncbi.nlm.nih.gov/2183100/)). The cholinergic, glutamatergic, and GABAergic neurons of the PPN have distinct effects on sleep/wake states ([Kroeger et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28039375/)): [@kroeger2017]
- Glutamatergic PPN neurons: Activation promotes prolonged cortical activation and wakefulness.
- Cholinergic PPN neurons: Activation suppresses lower-frequency EEG rhythms during NREM sleep, promoting cortical desynchronization.
- GABAergic PPN neurons: Activation slightly reduces REM sleep duration.
The link between PPN degeneration and REM sleep behavior disorder in parkinsonian syndromes reflects this critical role in sleep regulation. [@hirsch1987]
Arousal and Attention
Through its cholinergic projections to the thalamus, the PPN modulates thalamocortical transmission and cortical arousal. During wakefulness, acetylcholine from PPN neurons excites thalamocortical relay neurons while reducing activity in the thalamic reticular nucleus, facilitating sensory transmission to the cortex. Reduced cholinergic input during sleep has the opposite effect, promoting the thalamic oscillations characteristic of NREM sleep. [@bohnen2009]
Reward and Motivated Behavior
The PPN sends cholinergic projections to midbrain dopamine neurons in the VTA and SNc, modulating dopaminergic activity and contributing to reward-related learning and motivated behavior ([Xiao et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27477016/)). [@zweig1989]
Vulnerability in Neurodegenerative Disease
Parkinson's Disease
In Parkinson's disease, the PPN undergoes substantial cholinergic neuron loss. Post-mortem studies report a 40–60% reduction in ChAT-positive neurons in the PPN of PD patients compared to age-matched controls ([Hirsch et al., 1987](https://pubmed.ncbi.nlm.nih.gov/3108798/)). This degeneration contributes to the axial motor symptoms of PD that respond poorly to levodopa: [@thevathasan2018]
- Freezing of gait (FOG): Sudden, transient episodes of inability to initiate or continue walking. FOG affects approximately 60–80% of advanced PD patients and is a major cause of falls and disability.
- Postural instability: Impaired balance and postural reflexes, leading to retropulsion and frequent falls.
- Gait abnormalities: Reduced step length, shuffling gait, festination (progressively shortened, quickened steps).
PPN cholinergic denervation in PD has been confirmed in vivo using PET imaging with acetylcholinesterase tracers (11C-PMP), showing significantly reduced cortical and thalamic cholinergic innervation correlating with fall frequency ([Bohnen et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19297686/)). [@hamani2016]
The dual pathology theory proposes that the combined loss of dopaminergic neurons in the substantia nigra and cholinergic neurons in the PPN creates a synergistic deficit that produces gait and balance impairments beyond what either deficit alone would cause ([Pienaar et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31749893/)). [@henderson2016]
Progressive Supranuclear Palsy
progressive supranuclear palsy exhibits the most severe PPN degeneration among the parkinsonian disorders, with up to 75% loss of cholinergic neurons ([Zweig et al., 1989](https://pubmed.ncbi.nlm.nih.gov/2778218/)). Tau(/proteins/tau neurofibrillary tangles and neuropil threads extensively infiltrate the PPN, and the degree of PPN pathology correlates with the severity of gait disturbance and fall frequency in PSP. The early and severe postural instability and backward falls characteristic of PSP — often the presenting symptom — reflect this profound PPN cholinergic deficit combined with tau pathology] in the basal ganglia and brainstem.
Multiple System Atrophy
In multiple system atrophy, PPN neuronal loss contributes to the cerebellar ataxia (MSA-C subtype) and parkinsonism (MSA-P subtype) phenotypes. Combined degeneration of the PPN, cerebellum, and basal ganglia produces the complex motor dysfunction seen in MSA.
Lewy Body Dementia
In Lewy body dementia, PPN cholinergic degeneration is comparable to that in PD and contributes to the fluctuating cognition and REM sleep behavior disorder that are core features of DLB. The PPN is a major source of alpha-synuclein Lewy pathology in DLB.
Therapeutic Targeting
Deep Brain Stimulation of the PPN
PPN [deep brain stimulation](treatments/deep-brain-stimulation) (PPN-DBS) has emerged as an experimental therapy for levodopa-refractory gait freezing and postural instability in PD. Key findings from clinical studies ([Thevathasan et al., 2018](https://pubmed.ncbi.nlm.nih.gov/28960543/)):
- Stimulation parameters: Low-frequency stimulation (20–35 Hz) is used, in contrast to the high-frequency (>100 Hz) stimulation used for STN and GPi DBS.
- Efficacy: Meta-analyses suggest improvements in freezing of gait and fall frequency in selected patients, though results are variable between centers.
- Limitations: Fewer than 100 cases have been published worldwide; there is substantial heterogeneity in electrode placement, stimulation parameters, and outcome measures.
- Combined approach: PPN-DBS is often performed in conjunction with subthalamic nucleus DBS, targeting both dopaminergic and cholinergic deficits.
The challenge of PPN-DBS lies in the anatomical complexity of the target — the PPN is small, heterogeneous, and partially degenerated in the patients who are candidates for stimulation ([Hamani et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27723662/)).
Cholinergic Enhancement
Given the cholinergic basis of PPN degeneration in PD, cholinesterase inhibitors (e.g., donepezil, rivastigmine have been investigated for gait and balance impairments. Rivastigmine has shown modest benefits in reducing fall rates in PD patients in some clinical trials, supporting the role of cholinergic deficits in postural instability ([Henderson et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26889608/)).
Research Methods
Neuroimaging
- PET cholinergic imaging: 11C-PMP and 18F-FEOBV PET can quantify cholinergic terminal density in the PPN projection targets, revealing cholinergic denervation patterns in PD and DLB.
- Structural MRI: High-resolution brainstem MRI with diffusion tensor imaging (DTI) can identify the PPN region and map its white matter connections, aiding in DBS target planning.
- Functional MRI: Task-based fMRI during imagined walking reveals PPN activation patterns and their disruption in PD patients with gait freezing.
- [Cholinergic Neurons (Basal Forebrain)](/cell-types/neurons)
- [Deep Brain Stimulation (DBS)](treatments/deep-brain-stimulation)
External Links
- [Allen Human Brain Atlas — PPN Expression Data](https://human.brain-map.org/microarray/search/show?search_term=pedunculopontine)
- [Pedunculopontine Nucleus — ScienceDirect Topics](https://www.sciencedirect.com/topics/neuroscience/pedunculopontine-nucleus)
Brain Atlas Resources
This section links to atlas resources relevant to this brain region.
- Allen Human Brain Atlas: [Pedunculopontine Nucleus expression search](https://human.brain-map.org/microarray/search/show?search_term=Pedunculopontine+Nucleus)
- Allen Mouse Brain Atlas: [Pedunculopontine Nucleus search](https://mouse.brain-map.org/search/index.html?query=Pedunculopontine+Nucleus)
- Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
- BrainSpan Developmental Transcriptome: [Pedunculopontine Nucleus developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Pedunculopontine+Nucleus)
Background
The study of Pedunculopontine Nucleus (Ppn) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Unknown, Takakusaki K, Chiba R, Nozu T, Okumura T. Brainstem control of locomotion and muscle tone with special reference to the role of the mesopontine tegmentum and medullary reticulospinal systems. J Neural Transm. 2016;123(7):695-729. [PubMed (2016)](https://pubmed.ncbi.nlm.nih.gov/26972579/)
[Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson's Disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10704927/)
[Unknown, Pienaar IS, Vernon A, Bhagwan NR. Pharmacology of the pedunculopontine nucleus. In: Frontiers in Pharmacology. 2019;10:1494. [PubMed (2019)](https://pubmed.ncbi.nlm.nih.gov/31749893/)
[Mesulam MM, Mufson EJ, Wainer BH, Levey AI. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6) (1983)](https://pubmed.ncbi.nlm.nih.gov/6619325/)
[Unknown, Martinez-Gonzalez C, Bolam JP, Mena-Segovia J. Topographical organization of the pedunculopontine nucleus. Front Neuroanat. 2011;5:22. [PubMed (2011)](https://pubmed.ncbi.nlm.nih.gov/21383508/)
[Unknown, Mena-Segovia J, Bolam JP, Magill PJ. Pedunculopontine nucleus and basal ganglia: distant relatives or part of the same family? Trends Neurosci. 2004;27(10):585-588. [PubMed (2004)](https://pubmed.ncbi.nlm.nih.gov/15325346/)
[Unknown, Garcia-Rill E. The pedunculopontine nucleus. Prog Neurobiol. 1991;36(5):363-389. [PubMed (1991)](https://pubmed.ncbi.nlm.nih.gov/1786666/)
[Unknown, Steriade M, Datta S, Paré D, Oakson G, Curró Dossi RC. Neuronal activities in brain-stem cholinergic nuclei related to tonic activation processes in thalamocortical systems. J Neurosci. 1990;10(8):2541-2559. [PubMed (1990)](https://pubmed.ncbi.nlm.nih.gov/2183100/)
[Kroeger D, Ferrari LL, Petit G, et al., Cholinergic, glutamatergic, and GABAergic neurons of the pedunculopontine tegmental nucleus have distinct effects on sleep/wake behavior in mice. J Neurosci. 2017;37(5):1352-1366. [PubMed (2017)](https://pubmed.ncbi.nlm.nih.gov/28039375/)
[Unknown, Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in Progressive Supranuclear Palsy. Proc Natl Acad Sci USA. 1987;84(16):5976-5980. [PubMed (1987)](https://pubmed.ncbi.nlm.nih.gov/3108798/)
[Bohnen NI, Müller ML, Koeppe RA, et al., History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73(20):1670-1676. [PubMed (2009)](https://pubmed.ncbi.nlm.nih.gov/19297686/)
[Unknown, Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in Parkinson's Disease. Ann Neurol. 1989;26(1):41-46. [PubMed (1989)](https://pubmed.ncbi.nlm.nih.gov/2778218/)
[Thevathasan W, Debu B, Aziz T, et al., Pedunculopontine nucleus deep brain stimulation in Parkinson's Disease: a clinical review. Mov Disord. 2018;33(1):10-20. [PubMed (2018)](https://pubmed.ncbi.nlm.nih.gov/28960543/)
[Hamani C, Lozano AM, Mazzone PAM, et al., Pedunculopontine nucleus region deep brain stimulation in Parkinson disease: surgical anatomy and terminology. Stereotact Funct Neurosurg. 2016;94(5):298-306. [PubMed (2016)](https://pubmed.ncbi.nlm.nih.gov/27723662/)
[Henderson EJ, Lord SR, Brodie MA, et al. Rivastigmine for gait stability in patients with Parkinson's Disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial (2016)](https://pubmed.ncbi.nlm.nih.gov/26889608/)